{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:59:17Z","timestamp":1768471157917,"version":"3.49.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000877","name":"Rockefeller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018989","name":"Foundation for Advanced Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018989","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jbior.2022.100946","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T11:14:58Z","timestamp":1672485298000},"page":"100946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma"],"prefix":"10.1016","volume":"88","author":[{"given":"Meena","family":"Jhanwar-Uniyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Gellerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Bree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Kleinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag D.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jbior.2022.100946_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3892\/ijo.2021.5263","article-title":"Targeting the mTOR pathway using novel ATP competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma","volume":"59","author":"Amin","year":"2021","journal-title":"Int. J. Oncol."},{"issue":"7120","key":"10.1016\/j.jbior.2022.100946_bib2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2022.100946_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jbior.2022.100946_bib4","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-06-4180","article-title":"CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles","volume":"67","author":"Beier","year":"2007","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.jbior.2022.100946_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007752","article-title":"Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations","volume":"4","author":"Brennan","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jbior.2022.100946_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"issue":"7216","key":"10.1016\/j.jbior.2022.100946_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.jbior.2022.100946_bib8","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.15252\/emmm.201302627","article-title":"Emerging treatment strategies for glioblastoma multiforme","volume":"6","author":"Carlsson","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.jbior.2022.100946_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.stem.2009.06.017","article-title":"mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging","volume":"5","author":"Castilho","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jbior.2022.100946_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0092-8674(03)00392-1","article-title":"Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells","volume":"113","author":"Chambers","year":"2003","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jbior.2022.100946_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","article-title":"Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme","volume":"23","author":"Chang","year":"2005","journal-title":"Invest New Drugs. Aug"},{"key":"10.1016\/j.jbior.2022.100946_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jbior.2022.100946_bib13","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","article-title":"Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma","volume":"5","author":"Cloughesy","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.jbior.2022.100946_bib14","doi-asserted-by":"crossref","first-page":"9956","DOI":"10.1038\/srep09956","article-title":"Combined inhibition of AKT\/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells","volume":"5","author":"Daniele","year":"2015","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.jbior.2022.100946_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","article-title":"Regulation of mTORC1 by PI3K signaling","volume":"25","author":"Dibble","year":"2015","journal-title":"Trends Cell Biol."},{"issue":"3","key":"10.1016\/j.jbior.2022.100946_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jbior.2022.100946_bib17","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol."},{"issue":"4","key":"10.1016\/j.jbior.2022.100946_bib18","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3892\/or.2013.2625","article-title":"Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid","volume":"30","author":"Friedman","year":"2013","journal-title":"Oncol. Rep."},{"issue":"19","key":"10.1016\/j.jbior.2022.100946_bib19","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1158\/0008-5472.CAN-04-1364","article-title":"Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma","volume":"64","author":"Galli","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jbior.2022.100946_bib20","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","article-title":"Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2","volume":"11","author":"Garami","year":"2003","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.jbior.2022.100946_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"67","key":"10.1016\/j.jbior.2022.100946_bib22","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition","volume":"2","author":"Guertin","year":"2009","journal-title":"Sci. Signal."},{"issue":"4","key":"10.1016\/j.jbior.2022.100946_bib23","first-page":"731","article-title":"Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility","volume":"35","author":"Gulati","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbior.2022.100946_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2559.2011.03993.x","article-title":"Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas","volume":"59","author":"Guo","year":"2011","journal-title":"Histopathology"},{"issue":"25","key":"10.1016\/j.jbior.2022.100946_bib25","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.2036535100","article-title":"Cancerous stem cells can arise from pediatric brain tumors","volume":"100","author":"Hemmati","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.jbior.2022.100946_bib26","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1158\/0008-5472.CAN-18-3658","article-title":"Disruption of the scaffolding function of mLST8 selectively inhibits mTORC2 assembly and function and suppresses mTORC2-dependent tumor growth in vivo","volume":"79","author":"Hwang","year":"2019","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.jbior.2022.100946_bib27","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.jbior.2022.100946_bib28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.jbior.2022.100946_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.advenzreg.2010.09.017","article-title":"Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt\/mTOR and MAPK pathways","volume":"51","author":"Jhanwar-Uniyal","year":"2011","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.jbior.2022.100946_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jbior.2016.12.001","article-title":"Discrete signaling mechanisms of mTORC1 and mTORC2: connected yet apart in cellular and molecular aspects","volume":"64","author":"Jhanwar-Uniyal","year":"2017","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jbior.2022.100946_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbior.2019.03.003","article-title":"Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship","volume":"72","author":"Jhanwar-Uniyal","year":"2019","journal-title":"Adv Biol Regul"},{"issue":"S7","key":"10.1016\/j.jbior.2022.100946_bib32","doi-asserted-by":"crossref","first-page":"S1143","DOI":"10.21037\/tcr.2017.09.36","article-title":"Mighty RapaLink-1 vanquishes undruggable mutant mTOR in glioblastoma","volume":"6","author":"Jhanwar-Uniyal","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.jbior.2022.100946_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2021.100854","article-title":"Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma","volume":"83","author":"Jhanwar-Uniyal","year":"2022","journal-title":"Adv. Biol. Regulat."},{"issue":"8","key":"10.1016\/j.jbior.2022.100946_bib34","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/stem.98","article-title":"Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens","volume":"27","author":"Kelly","year":"2009","journal-title":"Stem Cell."},{"issue":"5","key":"10.1016\/j.jbior.2022.100946_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00063030-200721050-00002","article-title":"Selective targeting of cancer stem cells: a new concept in cancer therapeutics","volume":"21","author":"Korkaya","year":"2007","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.jbior.2022.100946_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.jbior.2022.100946_bib37","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1021\/jm101144f","article-title":"Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3- (trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer","volume":"53","author":"Liu","year":"2010","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jbior.2022.100946_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-009-9919-z","article-title":"Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors","volume":"94","author":"Liu","year":"2009","journal-title":"J. Neurooncol"},{"issue":"5","key":"10.1016\/j.jbior.2022.100946_bib39","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/jm101520v","article-title":"Discovery of 9-(6-aminopyridin-3-yl)-1-(3- (trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer","volume":"54","author":"Liu","year":"2011","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.jbior.2022.100946_bib40","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/jm101520v","article-title":"Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer","volume":"54","author":"Liu","year":"2011","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jbior.2022.100946_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","article-title":"Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control","volume":"10","author":"Loewith","year":"2002","journal-title":"Mol. Cell."},{"issue":"2","key":"10.1016\/j.jbior.2022.100946_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056324","article-title":"Embryonic stem cells markers SOX2, OCT4 and nanog expression and their correlations with epithelial mesenchymal transition in nasopharyngeal carcinoma","volume":"8","author":"Luo","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jbior.2022.100946_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"23","key":"10.1016\/j.jbior.2022.100946_bib45","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1158\/1078-0432.CCR-07-1229","article-title":"Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications","volume":"13","author":"Mangiola","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.jbior.2022.100946_bib46","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2174\/092986707781368423","article-title":"Targeting the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside","volume":"14","author":"Martelli","year":"2007","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.jbior.2022.100946_bib47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.1863","article-title":"Development of a novel mouse glioma model using lentiviral vectors","volume":"15","author":"Marumoto","year":"2009","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.jbior.2022.100946_bib49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signaling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.jbior.2022.100946_bib50","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3892\/ijo.2015.3311","article-title":"ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma","volume":"48","author":"Neil","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"19","key":"10.1016\/j.jbior.2022.100946_bib51","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1242\/dev.038893","article-title":"Suppression of Erk signaling promotes ground state pluripotency in the mouse embryo","volume":"136","author":"Nichols","year":"2009","journal-title":"Development"},{"issue":"Suppl. 5","key":"10.1016\/j.jbior.2022.100946_bib52","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.jbior.2022.100946_bib53","first-page":"1270","article-title":"Phase II study of PX-866 in recurrent glioblastoma","volume":"17","author":"Pitz","year":"2015","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.jbior.2022.100946_bib54","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1158\/0008-5472.CAN-09-3904","article-title":"Glioma cell populations grouped by different cell type markers drive brain tumor growth","volume":"70","author":"Prestegarden","year":"2010","journal-title":"Cancer Res."},{"issue":"6859","key":"10.1016\/j.jbior.2022.100946_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stemcells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"issue":"7606","key":"10.1016\/j.jbior.2022.100946_bib56","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.jbior.2022.100946_bib57","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.3390\/ijms20153824","article-title":"The autophagy status of cancer stem cells in gliobastoma multiforme: from cancer promotion to therapeutic strategies","volume":"20","author":"Ryskalin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.jbior.2022.100946_bib58","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.1074\/jbc.M809207200","article-title":"Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein","volume":"284","author":"Sato","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.jbior.2022.100946_bib59","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.jbior.2022.100946_bib60","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.31219","article-title":"Phase 1\/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: north Central Cancer Treatment Group Study\/Alliance N0572","volume":"124","author":"Schiff","year":"2018","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jbior.2022.100946_bib61","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1166\/jbn.2015.2146","article-title":"Synergistic effect of immunoliposomal gemcitabine and bevacizumab in glioblastoma stem cell-targeted therapy","volume":"11","author":"Shin","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"issue":"43","key":"10.1016\/j.jbior.2022.100946_bib62","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1038\/sj.onc.1207946","article-title":"Cancer stem cells in nervous system tumors","volume":"23","author":"Singh","year":"2004","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.jbior.2022.100946_bib63","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumors","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res."},{"issue":"7015","key":"10.1016\/j.jbior.2022.100946_bib64","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jbior.2022.100946_bib65","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.jbior.2022.100946_bib66","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1021\/jm3007933","article-title":"Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)","volume":"56","author":"Takeuchi","year":"2013","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.jbior.2022.100946_bib67","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbior.2022.100946_bib70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/jclinpath-2017-204815","article-title":"alSubcellular localisation of the stem cell markers OCT4, SOX2, NANOG, KLF4 and c-MYC in cancer","volume":"71","author":"Van Schaijik","year":"2018","journal-title":"Rev. J. Clin. Pathol."},{"key":"10.1016\/j.jbior.2022.100946_bib71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.jbior.2022.100946_bib72","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.18.01207","article-title":"Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial","volume":"37","author":"Wen","year":"2019","journal-title":"J Clin Oncol. Mar 20"},{"issue":"4","key":"10.1016\/j.jbior.2022.100946_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107571","article-title":"Rheb1-Independent activation of mTORC1 in mammary tumors occurs through activating mutations in mTOR","volume":"31","author":"Xiao","year":"2020","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.jbior.2022.100946_bib74","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noab269","article-title":"Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jbior.2022.100946_bib75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jbior.2022.100946_bib76","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2741\/4907","article-title":"Nanog promotes stem-like traits of glioblastoma cells","volume":"26","author":"Yuan","year":"2021","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"10.1016\/j.jbior.2022.100946_bib77","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492622000860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492622000860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:28:51Z","timestamp":1761949731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492622000860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":73,"alternative-id":["S2212492622000860"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2022.100946","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2022.100946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100946"}}